Farace Françoise, Bidart Jean-Michel
Laboratoire de recherche translationnelle, Institut de cancérologie Gustave-Roussy, 94805 Villejuif.
Bull Cancer. 2007 Jul;94 Spec No:S254-9.
Tumor vessel formation is largely dependent on the recruitment of endothelial cells. Rare in healthy individuals, circulating endothelial cells (CEC) are shed from vessel walls and enter the circulation reflecting endothelial damage or dysfunction. Increased numbers of CEC have been documented in different types of cancer. Recent studies have suggested the role for CEC in tumor angiogenesis, but whose presence could also reflect normal endothelium perturbation in cancer. Originating from the bone marrow rather than from vessel walls, endothelial progenitor cells (EPC) are mobilized following tissue ischemia and may be recruited to complement local angiogenesis supplied by existing endothelium. Recently, studies in mouse models suggest that the circulating fraction of endothelial progenitors (CEP) is involved in tumor angiogenesis but their contribution is less clear in humans. The detection of CEC and CEP is difficult and impeded by the rarity of these cells. They may have important clinical implication as novel biomarkers susceptible to predict more efficiently and rapidly the therapeutic response to anti-angiogenic treatments. However, a methodological consensus would be necessary in order to correctly evaluate the clinical interest of CEC and CEP in patients.
肿瘤血管形成很大程度上依赖于内皮细胞的募集。循环内皮细胞（CEC）在健康个体中很少见，它们从血管壁脱落并进入循环，反映出内皮损伤或功能障碍。在不同类型的癌症中，CEC数量增加已有文献记载。最近的研究表明CEC在肿瘤血管生成中起作用，但其存在也可能反映癌症中正常内皮的扰动。内皮祖细胞（EPC）起源于骨髓而非血管壁，在组织缺血后被动员，并可能被募集以补充现有内皮提供的局部血管生成。最近，小鼠模型研究表明，内皮祖细胞的循环部分（CEP）参与肿瘤血管生成，但它们在人类中的作用尚不清楚。CEC和CEP的检测很困难，因为这些细胞很罕见。它们作为新型生物标志物可能具有重要的临床意义，有望更有效、快速地预测抗血管生成治疗的疗效。然而，为了正确评估CEC和CEP在患者中的临床价值，需要达成方法学上的共识。
